Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03930953 · ClinicalTrials.gov registry record · Phase 1
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
A Phase 1 study of Lymphoma, Non-Hodgkin, sponsored by Celgene.
- Active
- Registry status
- Phase 1
- Development phase
- 438
- Enrollment target
- 20
- Study locations
NCT03930953: Active Phase 1 study of Lymphoma, Non-Hodgkin, sponsored by Celgene.
NCT03930953 is a Phase 1 study of Lymphoma, Non-Hodgkin that is active but no longer recruiting, run by Celgene. The registered enrollment target is 438 participants, above the 382-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (15% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03930953, a Phase 1 study of Lymphoma, Non-Hodgkin, is active but no longer recruiting, sponsored by Celgene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 438 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Rituximab
- DRUG Valemetostat
- DRUG Tafasitamab
- DRUG CC-99282
Study Locations (20)
Other
- Local Institution - 253 - Buenos Aires
- Local Institution - 701 - Salzburg
- Local Institution - 704 - Sankt Pölten
- Local Institution - 703 - Vienna
- Local Institution - 902 - Leuven
- Local Institution - 451 - São Paulo
- Local Institution - 452 - São Paulo
Florida
- Local Institution - 111 - Jacksonville
- Local Institution - 102 - Tampa
Buenos Aires
- Local Institution - 255 - Ciudad Autonoma de Buenos Aires
- Local Institution - 254 - Pilar
Arizona
- Local Institution - 109 - Scottsdale
Kansas
- Local Institution - 108 - Overland Park
Minnesota
- Local Institution - 107 - Rochester
Missouri
- Local Institution - 104 - St Louis
New Jersey
- Local Institution - 103 - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2028-02-09 |
| Phase | Phase 1 |
What the registry record for NCT03930953 still lists
NCT03930953 is an interventional study that assigns participants to a tested intervention. The registered 438 participants enrollment target is mid-sized for trials with a published cap, above the 382-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (15% higher).
The record links to 1 condition, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT03930953 names 20 study sites across 12 states, led by Other, Florida, Buenos Aires.
Frequently Asked Questions
What is clinical trial NCT03930953 about?
NCT03930953 is a clinical study titled "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)". The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
What is the current status of trial NCT03930953?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 438 participants. The study started on 2019-05-20. Estimated completion is 2028-02-09.
What conditions does trial NCT03930953 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT03930953?
The interventions under investigation include: Obinutuzumab (DRUG), Rituximab (DRUG), Valemetostat (DRUG), Tafasitamab (DRUG), CC-99282 (DRUG).
Who is sponsoring clinical trial NCT03930953?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03930953 being conducted?
This trial has 20 study locations across Arizona, Florida, Kansas, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03930953's enrollment target sits among peer trials
438 12th of 58 higher than 47 of 58 other Lymphoma, Non-Hodgkin trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Non-Hodgkin trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05711446 · 438 participants · NA
Double Voiding and Post-transplant UTI
- NCT06235151 · 439 participants · Phase 3
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI